Otsuka snaps up cancer/CNS venture Astex for $886m

Otsuka Holdings is to acquire the US firm Astex Pharmaceuticals for $8.50 per share, or around $886m, in a move that will expand the major diversified Japanese group's interests in both oncology and the CNS area in line with mid-term strategy.